정신병 시장 규모, 점유율 및 성장 분석 : 약제 클래스별, 질환 유형별, 투여 경로별, 약제 유형별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Global Psychosis Market size was valued at USD 12.59 Billion in 2024 and is poised to grow from USD 13.38 Billion in 2025 to USD 21.82 Billion by 2033, growing at a CAGR of 6.3% during the forecast period (2026-2033).

The global psychosis market encompasses a range of drugs, diagnostic products, and therapies aimed at treating schizophrenia, bipolar disorder, and similar conditions. With mental disorders impacting approximately 3% of the global population, the demand for effective treatments drives significant healthcare expenditures. Initially dominated by antipsychotics, the market has expanded due to the introduction of atypical medications and advancements in genetics and neuroimaging, enhancing patient stratification and fostering investments in precision medicine. Furthermore, the integration of real-world evidence (RWE) in drug development has transformed the landscape, allowing clinicians to gather valuable data on treatment efficacy through electronic health records (EHRs) and wearables. This facilitates the creation of novel therapies and encourages collaborations between biotech firms and manufacturers, propelling market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Psychosis market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Psychosis Market Segments Analysis

Global psychosis market is segmented by drug class, disorder type, route of administration, drug type, end user and region. Based on drug class, the market is segmented into Atypical Antipsychotics (Second Generation), Typical Antipsychotics (First Generation) and Long-Acting Injectable Antipsychotics (LAI). Based on disorder type, the market is segmented into Schizophrenia, Schizoaffective Disorder, Bipolar Disorder with Psychotic Features and Delusional Disorders. Based on route of administration, the market is segmented into Oral and Injectable (IM / LAI). Based on drug type, the market is segmented into Branded and Generic. Based on end user, the market is segmented into Hospitals & Psychiatric Clinics, Outpatient Facilities and Homecare. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Psychosis Market

One key market driver for the global psychosis market is the increasing prevalence of mental health disorders, which has prompted greater awareness and acceptance of psychological conditions. As society recognizes the importance of mental health, the demand for effective treatment options for psychosis has surged. This rise in interest has led to innovations in drug development, advancements in therapeutic approaches, and enhanced support systems. Additionally, growing investment in mental health care by governments and private organizations further contributes to the expansion of the market, facilitating better access to diagnostic tools and treatment solutions for individuals affected by psychosis.

Restraints in the Global Psychosis Market

One of the key market restraints for the global psychosis market is the stigma surrounding mental health disorders, which can hinder individuals from seeking timely diagnosis and treatment. This societal stigma often leads to a lack of understanding and acceptance, resulting in underreporting of psychotic symptoms and a general reluctance to access mental health services. Additionally, inadequate mental health infrastructure, particularly in developing regions, further compounds the issue by limiting access to necessary care and resources. These challenges can restrict market growth and diminish the effectiveness of available treatment options for individuals suffering from psychotic disorders.

Market Trends of the Global Psychosis Market

The Global Psychosis market is witnessing a substantial trend driven by the integration of AI-driven diagnostic tools, which are transforming the early detection and management of psychotic disorders. By utilizing advanced machine learning techniques to analyze speech patterns, facial expressions, and electronic health data, these innovative solutions enable healthcare professionals to identify early symptoms of psychosis with increased accuracy and efficiency. This proactive approach facilitates real-time risk assessment and enhances clinician responsiveness, paving the way for preventive interventions. As the demand for more effective and timely mental health care continues to rise, the adoption of such technology is poised to significantly enhance patient outcomes in the psychosis landscape.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Psychosis Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Atypical Antipsychotics (Second Generation)
• Typical Antipsychotics (First Generation)
• Long-Acting Injectable Antipsychotics (LAI)

Global Psychosis Market Size by Disorder Type & CAGR (2026-2033)

• Market Overview
• Schizophrenia
• Schizoaffective Disorder
• Bipolar Disorder with Psychotic Features
• Delusional Disorders

Global Psychosis Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Injectable (IM / LAI)

Global Psychosis Market Size by Drug Type & CAGR (2026-2033)

• Market Overview
• Branded
• Generic

Global Psychosis Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals & Psychiatric Clinics
• Outpatient Facilities
• Homecare

Global Psychosis Market Size & CAGR (2026-2033)

• North America (Drug Class, Disorder Type, Route of Administration, Drug Type, End User)
  • US
  • Canada
• Europe (Drug Class, Disorder Type, Route of Administration, Drug Type, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Disorder Type, Route of Administration, Drug Type, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Disorder Type, Route of Administration, Drug Type, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Disorder Type, Route of Administration, Drug Type, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Johnson & Johnson (Janssen)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Otsuka Pharmaceutical Co. Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lundbeck A/S
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alkermes plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intra-Cellular Therapies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acadia Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sunovion Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• H. Lundbeck
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations